383 



Mr. Bliley. Dr. Glenn, I am not a scientist but I was intrigued 

 by your testimony about the current focus of CTR research at the 

 molecular level in your belief that the keys to unlocking the mys- 

 teries of chronic diseases is to be found by this research. Would you 

 tell us some more about how your views compare with those of 

 other scientists? 



Mr. Glenn. I think my views are consistent and consonant with 

 the views of other scientists. 



One of the most significant things being done in medical science 

 today is the human genome project to which our government has 

 devoted a great deal of money and effort. In essence, once the 

 human genome is decoded we will be able to identify the genetic — 

 genetically normal patterns and the deviations from the normal 

 patterns that predisposes us to a lot of diseases. A theoretical pos- 

 sibility is that we could identify people who are subject to some dis- 

 ease in the future, and we could either genetically alter their gene's 

 chromosomes or we could advise them about avoiding the risk fac- 

 tors that might predispose them. It is a very exciting thing. 



Perhaps by the turn of the century we may have some very posi- 

 tive answers in this area. 



Mr. Bliley. Dr. Glenn, has CTR-funded research produced re- 

 sults which indicate connections or possible connections between 

 smoking and disease? 



Mr. Glenn. Yes, sir. 



Mr. Bliley. During your tenure, has CTR had a public relations 

 function? 



Mr. Glenn. No, sir. 



Mr. Bliley. Don't other funding organizations have PR func- 

 tions? 



Mr. Glenn. Well, to the extent that they engage in fund-raising 

 activities, we don't do that because we are funded by the industry. 

 The American Cancer Society, the American Heart Association, do 

 indeed have extensive public relations efforts, and it is entirely ap- 

 propriate that they do that, because they are raising money from 

 the general public in order to engage in research projects. 



Mr. Bliley. I noted. Dr. Glenn, in my opening remarks, my con- 

 cerns both about the misapprehension that can result from quoting 

 excerpts from documents out of context and the difficulty of accu- 

 rately developing the facts before this committee since we were not 

 provided until the last minute with the documents that will be 

 shown to witnesses. 



In a very short time I have had to review the Majority staff re- 

 port and its attachments. I note other documents not mentioned by 

 other members of this committee that should be brought to the 

 public's attention. In particular, I am going to read from Exhibit 

 8, which is a Hill and Knowlton memo dated July 31, 1954. It 

 seems to me pretty clear that from the beginning CTR was to be 

 involved in relevant research into tobacco issues and health. And 

 I will now begin to read. 



"In mid-December, 1953, executives of leading tobacco companies 

 decided some kind of joint action was imperative in the face of 

 widely publicized attacks alleging a link between cigarette smoking 

 and lung cancer. Representatives of Hill and Knowlton, Inc., were 



